KY61559X1045
KY61559X1045
MoonLake Immunotherapeutics
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 244.834.000 | 143.091.000 | 71.1% | |
| Operating Income | -244.834.000 | -143.091.000 | 71.1% |
| Pretax Income | -229.710.000 | -120.962.000 | 89.9% |
| Net Income Common Stockholders | -227.318.000 | -118.936.000 | 91.1% |
| -- | -- | -- | |
| -- | -- | -- |